.png)
AI is transforming antibody discovery, but better models only come from better data. When you are generating and screening sequences at scale, you need characterization results that are fast, comprehensive, and ready to use without hours of cleanup and reformatting.
Biointron built its gene-to-data platform exactly for this. Using mammalian cell expression, we deliver expression, affinity, and developability data in an integrated, high-throughput workflow that keeps up with the pace of AI-driven discovery. More data per cycle, faster turnaround, and the quality your models actually need to improve.
In this webinar, we will show you how it works and what it looks like in practice.
Learn more here: https://www.biointron.com/rushdata
Featuring Insights from
Lei Shi
,
PhD
Lei Shi, PhD is Senior Vice President of Biointron. He has more than 20 years of experience in antibody discovery.
Sponsored by
Biointron
In Partnership with
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
